Contents

Search


teriflunomide (Flucyamide, Aubagio, A77 1726)

Indications: - relapsing forms of multiple sclerosis* * not for rapidly evolving severe relapsing disease [NGC (NICE)] * on list of drugs to avoid for treatment of multiple sclerosis [5] - disproportionate adverse effects cited Contraindications: - pregnancy: X (teratrogenic) Dosage: - oral dosing Pharmacokinetics: - major metabolite of leflunomide Monitor: - negative TB testing before starting Aubagio - monthly for 1st 6 months then every 6 months - liver function tests - complete blood count (CBC) - serum amylase, serum lipase - blood pressure [4] Adverse effects: - same side effects as leflunomide - nausea, diarrhea, - alopecia - hepatotoxicity - increased risk of respiratory tract infection - tuberculosis - pancreatitis - elevated serum transaminases - lymphopenia - hypertension - peripheral neuropathy Notes: - costs about $3400/month in 2012 - compared to $4400 for Gilenya, $4000 for Copaxone (glatiramer), or $3745 for Avonex (beta-interferon)

General

amide pharmacologic metabolite

Database Correlations

PUBCHEM cid=5353833

References

  1. PubChem: 5353833
  2. Wikipedia: Teriflunomide http://en.wikipedia.org/wiki/Teriflunomide
  3. Prescriber's Letter 19(11): 2012 No Detail-Document (subscription needed) http://www.prescribersletter.com
  4. Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  5. Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/